Physician profile
Jonathan Warman
NPI 1083617534
$11,701.54
in general payments reported to CMS, 2019-2025
39 companies · $1,784 in 2025
The $1,784 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,330 · 2020: $896 · 2021: $1,185 · 2022: $2,050 · 2023: $2,134 · 2024: $2,323 · 2025: $1,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,240.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $2,478.40 | 2019-2025 | Sucraid, Sucraid |
| Abbvie INC. | $2,276.13 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Gilead Sciences, INC. | $1,644.97 | 2019-2025 | Biktarvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $975.35 | 2019-2024 | Trulance |
| Novo Nordisk INC | $595.17 | 2020-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $543.26 | 2019-2024 | Dificid, Delstrigo |
| Takeda Pharmaceuticals U.S.A., INC. | $479.89 | 2019-2025 | Entyvio, Gattex |
| Celltrion USA INC. | $206.19 | 2024-2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $150.25 | 2024 | Voquezna |
| Viiv Healthcare Company | $140.72 | 2020-2025 | Dovato |
| Ardelyx, INC. | $139.02 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $136.07 | 2022-2025 | |
| Vivus LLC | $125.90 | 2024-2025 | Qsymia |
| Allergan, INC. | $124.36 | 2019 | |
| Idorsia Pharmaceuticals US INC | $121.15 | 2022-2023 | Quviviq |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $113.24 | 2024 | Tremfya |
| Intra-Sana Laboratories | $107.38 | 2023-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Glaxosmithkline, LLC. | $102.54 | 2021 | |
| Celgene Corporation | $97.95 | 2023-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $96.14 | 2019 | |
| Intercept Pharmaceuticals, INC. | $94.83 | 2020-2023 | Ocaliva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.34 | 2023 | Cyltezo |
| Daiichi Sankyo INC. | $87.54 | 2019-2021 | |
| Redhill Biopharma INC. | $76.41 | 2020-2024 | Talicia |
| Ironwood Pharmaceuticals, INC | $75.04 | 2019-2022 | |
| Eisai INC. | $72.64 | 2019 | |
| Braintree Laboratories, INC. | $66.36 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $62.59 | 2019-2020 | |
| Lilly USA, LLC | $57.13 | 2024-2025 | Omvoh |
| Exact Sciences Corporation | $49.02 | 2025 | Cologuard Collection Kit |
| Shire North American Group INC | $47.68 | 2019 | |
| Emd Serono, INC. | $43.55 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.51 | 2022 | |
| Pfizer INC. | $43.22 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $38.36 | 2024 | Breztri |
| Organon LLC | $32.86 | 2024 | |
| Ambu INC. | $22.79 | 2024 | |
| Amgen INC. | $21.26 | 2025 | Uplizna |
| Bavarian Nordic A/S | $18.33 | 2025 | Vivotif |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Warman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.